Get the Stockscreener App
9.23
0.97%
-0.09
Emergent Biosolutions Inc stock is traded at $9.23, with a volume of 1.23M.
It is down -0.97% in the last 24 hours and up +28.91% over the past month.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
See More
Previous Close:
$9.32
Open:
$9.45
24h Volume:
1.23M
Relative Volume:
0.96
Market Cap:
$492.43M
Revenue:
$1.02B
Net Income/Loss:
$-757.20M
P/E Ratio:
-0.6253
EPS:
-14.76
Net Cash Flow:
$-257.90M
1W Performance:
+4.41%
1M Performance:
+28.91%
6M Performance:
+19.71%
1Y Performance:
-2.84%
1-Day Range:
$9.225
$9.66
1-Week Range:
$8.80
$9.66
52-Week Range:
$4.02
$12.73
Emergent Biosolutions Inc Stock (EBS) Company Profile
Name
Emergent Biosolutions Inc
Sector
Phone
240-631-3200
Address
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
9.23 | 483.89M | 1.02B | -757.20M | -257.90M | -14.76 |
|
ZTS
Zoetis Inc
|
156.62 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.52 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.46 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
312.23 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-07-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Aug-29-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-10-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-10-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-29-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-20-22 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-08-21 | Downgrade | The Benchmark Company | Buy → Hold |
| May-05-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Initiated | The Benchmark Company | Buy |
| Feb-24-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-19-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jan-08-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Jul-31-20 | Reiterated | Chardan Capital Markets | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| Sep-04-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-02-18 | Upgrade | Goldman | Neutral → Buy |
| Aug-03-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-13-18 | Initiated | Argus | Buy |
| Apr-25-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Jan-16-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-28-16 | Reiterated | Singular Research | Buy |
| Apr-15-16 | Initiated | Chardan Capital Markets | Buy |
| Mar-28-16 | Initiated | Singular Research | Buy |
| Feb-19-16 | Initiated | Wells Fargo | Outperform |
| May-15-14 | Initiated | Summer Street Research | Buy |
| May-31-11 | Reiterated | WBB Securities | Strong Buy |
| Jan-10-11 | Reiterated | Wedbush | Outperform |
| Nov-05-10 | Reiterated | Wedbush | Outperform |
| Aug-18-10 | Upgrade | WBB Securities | Buy → Strong Buy |
| Aug-06-10 | Reiterated | Caris & Company | Buy |
View All
Emergent Biosolutions Inc Stock (EBS) Latest News
Analysts Apply Wyckoff Model to Emergent BioSolutions Inc. Stock2025 Market WrapUp & Fast Moving Market Watchlists - beatles.ru
Technical Bounce Expected in Emergent BioSolutions Inc. Next WeekJuly 2025 Analyst Calls & Risk Managed Trade Strategies - thegnnews.com
Emergent BioSolutions : From Cost Center to Value Driver - MarketScreener
Three Analyst Favorites with Potential for Further Gains: SkyWater Technology, Emergent BioSolutions, and More - AInvest
Is Emergent BioSolutions Inc. stock forming a cup and handleTrade Volume Summary & High Conviction Buy Zone Picks - thegnnews.com
Emergent BioSolutions Board Member Sells $67K in Company Stock Amid Revenue Decline. - AInvest
Emergent BioSolutions signs contract modification award for CNJ-016 - MSN
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Emergent BioSolutions (EBS) Investors with $100k+ Losses to Contact Its Attorneys Now, Securities Fraud Case Pending, Firm Investigating CEO’s Insider Sales - ACCESS Newswire
Emergent BioSolutions' (NYSE:EBS) Solid Earnings May Rest On Weak Foundations - simplywall.st
Emergent BioSolutions Inc. (NYSE:EBS) Held Back By Insufficient Growth Even After Shares Climb 27% - 富途牛牛
We Think That There Are Some Issues For Emergent BioSolutions (NYSE:EBS) Beyond Its Promising Earnings - Yahoo Finance
Emergent BioSolutions Inc. Outperforms Peers on Volume MetricsQuarterly Risk Review & Smart Allocation Stock Reports - newsyoung.net
RSI Suggests Rebound May Be Near in Emergent BioSolutions Inc.2025 Volume Leaders & Daily Stock Momentum Reports - beatles.ru
Emergent BioSolutions Director Sells 7,844 Shares at $8.65/Share on August 12, 2025. - AInvest
Emergent BioSolutions’ Earnings Call Highlights Strong Financial Performance - The Globe and Mail
Emergent BioSolutions’ Strong Q2 Fuels Hopes for 2025 Rally - citybiz
300 new jobs headed to Bayview manufacturing plant - The Business Journals
Emergent BioSolutions: Q2 Results Could Spark A Strong 2025 Rally - Seeking Alpha
Emergent Biosolutions: Strategic Advancements and Financial Performance Drive Buy Rating - TipRanks
Emergent BioSolutions Reports Improved Q2 2025 Results - TipRanks
Published on: 2025-08-10 18:27:00 - metal.it
Earnings Update: Here's Why Analysts Just Lifted Their Emergent BioSolutions Inc. (NYSE:EBS) Price Target To US$13.50 - simplywall.st
Emergent BioSolutions Inc. (NYSE:EBS) Q2 2025 Earnings Call Transcript - Insider Monkey
Emergent Biosolutions (EBS) Q1 Earnings Top Estimates - MSN
Emergent BioSolutions' Strong ROE Amid Industry Average: A Financial Analysis - AInvest
Can Emergent BioSolutions Inc. (NYSE:EBS) Maintain Its Strong Returns? - Yahoo Finance
Emergent BioSolutions to participate in investor conferences in May and June 2025. - AInvest
Benchmark Co. Maintains Emergent BioSolutions(EBS.US) With Buy Rating, Maintains Target Price $12 - 富途牛牛
Emergent BioSolutions Updates FY25 Revenue Guidance to $765M-$835M - AInvest
BioPharma Co.'s $15M Deal Over Ruined J&J Vaccines OK'd - Law360
Emergent BioSolutions Surpasses Q2 Revenue Expectations - The Globe and Mail
Emergent BioSolutions reports Q2 adjusted EPS 16c vs ($2.32) last year - TipRanks
Emergent BioSolutions Soars 22% on Earnings Surprise: What's Fueling the Surge? - AInvest
Emergent Biosolutions reports second quarter loss - Maryland Daily Record
Emergent Biosolutions shares rise 6.14% premarket after securing $51.9 million contract modification for smallpox preparedness. - AInvest
Installed Building Products reports record Q2 2025 results, 3.1% revenue increase. - AInvest
Emergent Biosolutions Q2 Earnings Report: $12 Million LossNews and Statistics - IndexBox
Emergent Biosolutions: Q2 Earnings Snapshot - Huron Daily Tribune
Emergent BioSolutions Inc. SEC 10-Q Report - TradingView
Earnings call transcript: Emergent BioSolutions Q2 2025 results show mixed performance - Investing.com
Emergent BioSolutions Outpaces Its Own Forecasts But Misses Analyst Targets - Finimize
Emergent Biosolutions earnings beat by $0.26, revenue fell short of estimates - Investing.com Canada
Emergent BioSolutions Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Emergent BioSolutions Q2 revenue misses analyst expectations - MarketScreener
Emergent BioSolutions Inc Q2 2025 Earnings: EPS of -$0.22 Beats Estimates, Revenue Surges to $140.9 Million - GuruFocus
Emergent BioSolutions Q2 2025 slides: Profitability improves as transformation continues - Investing.com Canada
Emergent Biosolutions Q2 Earnings: Non-GAAP EPS Beats by $0.65, Revenue Misses by $5.47M - AInvest
Emergent BioSolutions Reports Second Quarter 2025 Financial Results - The Manila Times
Emergent BioSolutions Inc expected to post a loss of 49 cents a shareEarnings Preview - TradingView
What drives Emergent BioSolutions Inc. stock priceInvest confidently with real-time data analysis - Jammu Links News
Is it the right time to buy Emergent BioSolutions Inc. stockMaximize your portfolio’s growth potential - Jammu Links News
Emergent Biosolutions Inc Stock (EBS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.37%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):